Search 

Lysoway Therapeutics is an emerging biopharmaceutical company focusing on restoring or enhancing autophagy and lysosomal functions to treat a broad class of diseases.

Mitochondria play a central role in metabolic diseases and cancer. Targeting mitochondria for therapeutic development provides a unique opportunity for the effective treatment of these devastating diseases, including nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and various cancers.

Mito Biopharma is a leading company in designing safe chemical mitochondrial uncouplers for
therapeutic development. We have developed a transformative and proven platform technology supporting lead development. Proof-of-concept studies demonstrated broad applications of the platform and superiority of mechanism of action. Therapeutic leads are protected by strong IP protection (worldwide composition-of-matter patent protection). The technology impacts high-value markets including NASH/T2D, Covid-19, and cancer.

We have IND- leads for NASH/T2D, Covid-19, and liver metastatic cancer. Our current focus is on a NASH lead. The company is seeking resources to support the NASH lead for IND and Phase I development, as well as pipeline development.

MSQ Ventures is a New York-based cross-border advisory firm that bridges the healthcare industries globally by offering our deep knowledge, strong network, and local insights into the China market. We provide comprehensive advisory services for our clients’ cross-border projects: market assessment, in/out-licensing, joint ventures, and PR&IR. We currently have offices in New York (headquarter), Beijing, Shanghai, and Shenzhen.

Private investment firm

Pleiogenix is a clinical-stage bio-pharmaceutical company that will develop safe and effective treatments for liver and other diseases with significant unmet medical needs. The initial disease that Pleiogenix is targeting is alcoholic hepatitis (AH), with additional diseases to follow (COVID-19, Fibrosis, and NASH) . AH is a deadly liver disease resulting in mortality in most patients within 6 months, in the absence of a liver transplant. The global and US prevalence is 20-25%. The AH market is estimated to be $1.2 Billion in 2025, having a current annual growth rate of 6% (2019-2025). There are no approved efficacious therapeutics for the prevention or treatment of AH (dexamethasone reduces inflammation). The target patients for therapy include those with moderate and severe forms of AH. Pleiogenix has identified a Phase 2A-ready drug candidate, PLG888, an orally available, pan-PPAR agonist (non-thiazolidinedione) that increases circulating adiponectin without eliciting body weight gain or edema. Adiponectin is a hormone possessing significant anti-inflammatory, anti-fibrotic, and multiple metabolic clinical benefits. In patients suffering from AH, inflammation is severely increased. In animal models of NASH, increased adiponectin is linked to decreased systemic inflammation, increased hepatic fat oxidation, decreased hepatic fibrosis, and amelioration of NASH. Thus, PLG888 has the potential to become the first prescription pharmaceutical that exhibits multiple beneficial effects, in the context of AH.

VC investment focus on healthy care

Usurpo are a UK based specialist search firm focused on helping high-growth Life Sciences businesses hire outstanding executives worldwide. We have successfully run search campaigns in EMEA, ASIA PAC, India and the US.

We work closely with Pharmaceutical, Biotechnology, Medical Device companies and service providers to help them build exceptional leadership teams, particularly across Europe and the US. We have a track record of helping international business from China, Japan, Israel and Korea make key hires in the US and Europe for their expanding international teams.

We help our clients to hire Senior Director, VP and C-suite level professionals into the following areas:

- Clinical Development (Chief Medical Officer, Chief Development Officer, Medical Director, Therapeutic area experts)
- Regulatory Affairs
- CMC
- Business Development (Licensing, M&A, Corporate Development)
- Business Development (Sales and business expansion for service providers)
- Cross functional C-suite leadership
- Sales and Marketing leaders

Viva BioInnovator ("VBI") is the investment division of Viva Biotech Holdings (1873.HK). We are solely dedicated to the identification and success of early-stage, biotech start-ups for Viva’s incubation, equity-for-service, and investment platforms. Our commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.

healthcare VC